key: cord-0978818-r2el7c0h
authors: Geraci, Travis C.; Kon, Zachary N.; Moazami, Nader; Chang, Stephanie H.; Carillo, Julius; Chen, Stacey; Fargnoli, Anthony; Alimi, Marjan; Pass, Harvey; Galloway, Aubrey; Smith, Deane E.
title: Hemoadsorption for management of patients on veno‐venous ECMO support for severe COVID‐19 acute respiratory distress syndrome
date: 2021-07-04
journal: J Card Surg
DOI: 10.1111/jocs.15785
sha: 72f2a714a950ba29f3aaffc815fcbd56805fb702
doc_id: 978818
cord_uid: r2el7c0h

BACKGROUND AND AIM: Patients with severe coronavirus disease 2019 (COVID‐19) develop a profound cytokine‐mediated pro‐inflammatory response. This study reports outcomes in 10 patients with COVID‐19 supported on veno‐venous extracorporeal membrane oxygenation (VV‐ECMO) who were selected for the emergency use of a hemoadsorption column integrated in the ECMO circuit. MATERIALS AND METHODS: Pre and posttreatment, clinical data, and inflammatory markers were assessed to determine the safety and feasibility of using this system and to evaluate the clinical effect. RESULTS: During hemoadsorption, median levels of interleukin (IL)−2R, IL‐6, and IL‐10 decreased by 54%, 86%, and 64%, respectively. Reductions in other markers were observed for lactate dehydrogenase (−49%), ferritin (−46%), d‐dimer (−7%), C‐reactive protein (−55%), procalcitonin (−76%), and lactate (−44%). Vasoactive‐inotrope scores decreased significantly over the treatment interval (−80%). The median hospital length of stay was 53 days (36–85) and at 90‐days post cannulation, survival was 90% which was similar to a group of patients without the use of hemoadsorption. CONCLUSIONS: Addition of hemoadsorption to VV‐ECMO in patients with severe COVID‐19 is feasible and reduces measured cytokine levels. However, in this small series, the precise impact on the overall clinical course and survival benefit still remains unknown.

assess the safety and feasibility of hemoadsorption in this population. Secondarily, we assessed the anti-inflammatory efficacy of adsorption by comparison of pre and posttreatment levels of cytokines, inflammatory markers, and clinical parameters.

A single-institution retrospective analysis was conducted of patients with severe COVID-19 and respiratory failure placed on VV-ECMO, with the addition of hemoadsorption at New York University Langone Health from March 10, 2020 to June 30, 2020. Cytosorb adsorption is not currently approved by the United States Food and Drug Administration. In the midst of the COVID-19 pandemic, however, we obtained emergency use authorization for select patients. The primary objective of this study was to determine the safety and feasibility of hemoadsorption therapy based on clinical outcomes, including adverse events and survival. Secondarily, pre and posttreatment levels of select cytokines, biochemical data, and inflammatory markers were assessed to determine treatment effect.

All data were collected in a prospective database and demographic, clinical, and outcomes data were collected retrospectively from the electronic medical record. Follow-up was performed until hospital discharge, or 90 days post cannulation, whichever occurred first.

Study design, emergency use authorization, and data management were approved by the Institutional Review Board (IRB) at New York University Langone Health (IRB #S20-01189). Additionally, IRB approval was granted for informed consent to be obtained from family members and/or health care decision-makers on the patient's behalf given the severity of illness and need for sedation.

The diagnosis of COVID-19 was established by nasal pharyngeal swab for reverse-transcriptase polymerase chain reaction assay.

Patients were evaluated, cannulated for VV-ECMO, and managed by a multidisciplinary team of cardiothoracic surgeons and critical care physicians. 5 Entry and inclusion criteria were based on the arterial partial pressure of oxygen (PaO 2 )-to-fraction of inspired oxygen (FiO 2 ) ratio (P/F ratio), arterial blood gas, ventilator settings, and patient functional status, comorbidities, and hemodynamic status.

ECMO support was only offered to patients with a P/F ratio of less than 150 mmHg or a pH of less than 7.25 with a partial pressure of arterial carbon dioxide (PaCO 2 ) exceeding 60 mm Hg. 5 A lungprotective ventilation strategy was employed with titration of ECMO circuit flow, which was maintained above 3 L/min to limit oxygenator thrombosis. Oxygenator FiO 2 was maintained at 1.0 for the entirety of support. The sweep gas flow rate was adjusted to achieve a goal partial pressure of carbon dioxide (PCO 2 ) less than 45 mm Hg. Anticoagulation using intravenous heparin infusion was used to achieve a partial thromboplastin time goal of 50-70 and/or anti-Xa level more than 0.15 units/ml based on prior experience. 11, 12, 20 Vasopressors were used as needed to maintain a mean arterial pressure goal of 60 mm Hg.

The ECMO multidisciplinary team also evaluated patients for hemoadsorption. Hemoadsorption was added to the circuit in selected patients based on severity of illness-those who had progressive clinical decline while supported on VV-ECMO-including assessment of the P/F ratio, arterial blood gas values, ventilator, and ECMO settings, and hemodynamic status, particularly if those requiring high dose vasopressors. Patients with thrombocytopenia less than 20,000/µl or with a history of heparin-induced thrombocytopenia (HIT) were excluded per established contraindications to use.

There were no other absolute exclusion criteria.

In select patients on VV-ECMO, a hemoadsorption column (300 ml device) was installed in parallel with the ECMO circuit in a prehemofilter position ( Figure 1 ). Filtered blood returned to the venous line before the centrifugal pump. An additional ultrasonic flow probe was placed to calculate flow through the cartridge. All device integrations and exchanges required a brief suspension of ECMO.

Treatment was planned for a 72-h duration with device exchange every 12 h for the first 24 h, then 24 h thereafter, or as needed in the event of cartridge thrombosis.

Descriptive analyses for categorical variables are reported in Tables 1 and 3 as frequency and percentage. Continuous variables are reported as means and standard deviations or errors for normally distributed variables and as either means and range or medians and interquartile ranges for non-normally distributed variables. Single one-way analysis of variance test was performed for inflammatory and cytokine markers for data compiled per group time points of (−1 day before treatment), during the course (24, 48, and 72 h), and post (2-3 days after removal) to assess changes in overall profile. Inflammatory, metabolic, and clinical data reported in Table 3 hemodynamic support with a median vasoactive inotrope score was 4.79. Patients selected for hemoadsorption were hospitalized for a median of 4.5 days (IQR 1. 8-11.5) before ECMO and were supported on EMCO a median of 1 day (IQR 0-3) before the initiation of treatment. Baseline demographic information and clinical characteristics are reported in Table 1 .

Of the 10 patients selected for hemoadsorption, eight patients completed a full 72-h treatment duration, and there were no complications or adverse events in eight patients ( Table 2 ). One patient was removed from treatment after 24 h due to an inability to maintain adequate paralysis and sedation, which subsequently improved with cessation of hemoadsorption. Another patient developed HIT and the device was removed after 60 h of treatment. There was no evidence of progressive end-organ injury attributed to therapy with reductions in median levels of pre and posthemoadsorption in creatinine (−7%) and aspartate aminotransferase/ alanine aminotransferase levels (−10%/−40%). 

After the planned 72-h treatment course, patients who underwent hemoadsorption, had a median decrease in levels of interleukin (IL) 2 Receptor (IL-2R), IL-6, and IL-10 by 54%, 86%, and 64%, respectively 

Overall survival of patients who underwent hemoadsorption on VV-ECMO was 90% (9/10 patients) ( (Table 2 ). In the setting of full heparin anticoagulation in all patients, thrombocytopenia was observed in the majority of patients (60%). This reduction, however, did not result in bleeding events.

Previous series of critically ill patients undergoing hemoadsorption have reported modest reductions in platelet count, which were typically mild (<10%) and self-limiting. 21 In our series, one patient developed HIT and was removed from treatment after 60 h. It was unclear, however, whether the device was the precipitating factor for HIT. In our previously published series, 4/17 patients (24%) with severe COVID-19 on VV-ECMO without hemoadsorption, tested positive for HIT by platelet factor 4 antibody assay, two of which were confirmed positive by serotonin release assay. Given these findings, nonetheless, close monitoring for thrombocytopenia and HIT during hemoadsorption is warranted. Additionally, in three patients, the device required unplanned exchange for cartridge thrombosis, all of which were of low clinical impact.

Three patients required increased dosing of sedatives and neuromuscular blockade agents, including one patient who was removed from treatment after 24 h due to an inability to maintain adequate paralysis and sedation. A number of in-vitro and in-vivo studies have shown reduced or eliminated levels of analgesics, sedatives, and The clinical consequence of the clearance of inflammatory mediators remains unanswered; the number of patients in this series is small and the study is underpowered to detect subtle differences.

Given that the use of hemoadsorption was through an emergency use authorization in the context of an evolving pandemic, we were not able to perform a comparative trial of patients on ECMO with and without hemoadsorption. There were, however, some notable clinical outcomes observed. Of the seven patients requiring vasopressor and/or inotropic support pre-CytoSorb, only two required hemodynamic support afterinitiation of hemoadsorption and these levels were significantly reduced. The pre and posttreatment median vasopressin inotropic scores decreased by 80% during the 3-day treatment interval. In patients who underwent VV-ECMO with Cy-tosSorb, median hospital length of stay was 53 days (36-85) and

survival was 90% with eight patients discharged and one patient hospitalized at 90-days post ECMO cannulation. This patient was discharged to an acute rehabilitation facility after a 160 day length of stay and discharged home after 33 days of rehabilitation.

The survival rate in this series is substantially higher than other institutional reports of patients on VV-ECMO for COVID-19, with survival to discharge rates between 56.8% and 62%. 7, 8 In this small study, the causal contribution of hemoadsorption towards respiratory recovery and survival is unproven. Furthermore, in the patients on hemoadsorption, the column was removed after 72 h of usage. It is unclear if longer duration of support would have contributed to clinical recovery. This study is further limited by its retrospective, single-center design with limited sample size, and is therefore underpowered for definitive lung recovery or survival analysis. Patients were selected for the addition of hemoadsorption in a nonrandom fashion based on severity of illness. There was an inherent selection bias, therefore, for patients with more severe disease, given the lack of clear inclusion or exclusion criteria.

Given the limited therapeutic options available for severely ill patients 

Lactate dehydrogenase, U/L, median (IQR)

/ml, median (IQR) 2647

ng/ml, median (IQR)

mg/dL, median (IQR)

Procalcintonin, ng/ml, median (IQR)

pg/ml, median (IQR)

pg/ml, median (IQR)

IL-10, pg/ml, median (IQR) 18 (9

Platelet count, 1000/µl, median (IQR)

Creatinine, mg/dL, median (IQR)

PCO 2 , mm Hg, median (IQR)

FiO 2 , %, median (IQR)

PaO 2 /FiO 2 (P:F ratio), median (IQR)

Abbreviations: FiO 2 , fraction of inspired oxygen

Grouped %change reported as per individual patient as (72 h -Pre)/Pre, mean of change p <

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Extracorporeal membrane oxygenation support in severe COVID-19

Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure

Extracorporeal life support organization. extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): multicenter experience of referral hospitals in a large health care system

Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment

Rationale of hemoadsorption during extracorporeal membrane oxygenation support

Cytokine adsorption in critically ill patients requiring ECMO support

Additive treatment considerations in COVID-19: the clinician's perspective on extracorporeal adjunctive purification techniques

Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report

Combined use of CytoSorb and ECMO in patients with severe pneumogenic sepsis

Hemoadsorption by CytoSorb in septic patients: a case series

Treatment of postcardiopulmonary bypass SIRS by hemoadsorption: a case series

Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass: a case series

Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: A case series

Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review

CytoSorb 300 mL Device: Approved by FDA for Emergency Treatment of COVID-19

What have we learned about the use of Cytosorb adsorption columns?

Can cytokine adsorber treatment affect antibiotic concentrations? A case report

International registry on the use of the CytoSorb adsorber in ICU patients: study protocol and preliminary results

How to cite this article

Hemoadsorption for management of patients on veno-venous ECMO support for severe COVID-19 acute respiratory distress syndrome